Health system intelligence profile
Mount Sinai Health System (Mount Sinai Innovation Partners)
Editorially verified · Last reviewed August 30, 2026
Intelligence summary
Established 2018
The i3 Asset Accelerator is Mount Sinai Innovation Partners' milestone-driven investment program for advancing discoveries by Mount Sinai faculty, physicians and researchers toward commercial viability. Technologies are nominated by MSIP business development staff and then reviewed by an Investment Advisory Committee of venture capitalists, entrepreneurs and industry professionals from pharma, biotech and medical devices. Selected projects receive staged funding tied to defined commercial inflection points, with the explicit goals of generating stronger intellectual property, licensing assets to corporations or new startups, and attracting outside investment. Projects are judged on commercial inflection point, market potential, technological novelty and clinical relevance.
Documented successes: Launched publicly in 2018 as the i3 Asset Accelerator to advance development of Mount Sinai discoveries; operates with an external Investment Advisory Committee of VCs and industry executives that gates milestone-based funding; supported by Mount Sinai Innovation Partners' broader licensing and startup formation infrastructure
Mandate and remit
The i3 Asset Accelerator is Mount Sinai Innovation Partners' milestone-driven investment program for advancing discoveries by Mount Sinai faculty, physicians and researchers toward commercial viability. Technologies are nominated by MSIP business development staff and then reviewed by an Investment Advisory Committee of venture capitalists, entrepreneurs and industry professionals from pharma, biotech and medical devices. Selected projects receive staged funding tied to defined commercial inflection points, with the explicit goals of generating stronger intellectual property, licensing assets to corporations or new startups, and attracting outside investment. Projects are judged on commercial inflection point, market potential, technological novelty and clinical relevance.
These routes appear in the program's sourced public record.
Fund or office: i3 Asset Accelerator
The i3 Asset Accelerator is Mount Sinai Innovation Partners' milestone-driven investment program for advancing discoveries by Mount Sinai faculty, physicians and researchers toward commercial viability. Technologies are nominated by MSIP business development staff and then reviewed by an Investment Advisory Committee of venture capitalists, entrepreneurs and industry professionals from pharma, biotech and medical devices. Selected projects receive staged funding tied to defined commercial inflection points, with the explicit goals of generating stronger intellectual property, licensing assets to corporations or new startups, and attracting outside investment. Projects are judged on commercial inflection point, market potential, technological novelty and clinical relevance.
Documented successes
Launched publicly in 2018 as the i3 Asset Accelerator to advance development of Mount Sinai discoveries; operates with an external Investment Advisory Committee of VCs and industry executives that gates milestone-based funding; supported by Mount Sinai Innovation Partners' broader licensing and startup formation infrastructure
Organizational home: i3 Asset Accelerator, Mount Sinai Health System (Mount Sinai Innovation Partners)
Use the program's published contact route for partnership, licensing, innovation, or program inquiries.
Comparable records based on shared public taxonomy, location, or commercialization route.
Same state · Same program type · Same commercialization route
Albany, New York
Office of Translational Research, Innovation, and Technology Transfer (OTR)
The Office of Translational Research, Innovation, and Technology Transfer supports Albany Medical College inventors in moving biomedical discoveries toward commercialization.
Academic · Nonprofit
Read the intelligence briefReviewed August 30, 2026
Same state · Same program type · Same commercialization route
New York, New York
Columbia Technology Ventures
Columbia Technology Ventures (CTV) is the technology transfer and commercialization office for Columbia University, including its medical center faculty and clinicians.
Academic · Nonprofit
Read the intelligence briefEditorially verified · Reviewed August 30, 2026
Same state · Same program type · Same commercialization route
Ithaca, New York
Center for Technology Licensing (CTL)
The Center for Technology Licensing is the commercialization arm of Cornell University, with a dedicated office serving Weill Cornell Medicine in New York City.
Academic · Nonprofit
Read the intelligence briefEditorially verified · Reviewed August 30, 2026
Same state · Same program type · Same commercialization route
New York, New York
HSS Innovation Institute
The HSS Innovation Institute develops and commercializes musculoskeletal healthcare technologies originating from Hospital for Special Surgery clinicians and researchers.
Nonprofit
Read the intelligence briefReviewed August 30, 2026
Same state · Same program type · Same commercialization route
New York, New York
Office of Entrepreneurship and Commercialization (OEC)
The Office of Entrepreneurship and Commercialization is Memorial Sloan Kettering's technology commercialization arm, renamed from the Office of Technology Development in October 2024.
Nonprofit
Read the intelligence briefReviewed August 30, 2026
Same state · Same program type · Same commercialization route
Bronx, New York
Office of Biotechnology and Business Development
The Office of Biotechnology and Business Development is the technology transfer and industry-partnering office for Albert Einstein College of Medicine within the Montefiore Einstein system.
Academic · Nonprofit
Read the intelligence briefReviewed August 30, 2026
Reviewed August 30, 2026. External source links open in a new tab.
Confidential comparison
Request a confidential conversation about the commercial opportunities, market pathways, and capabilities within your hospital's innovation portfolio. The public directory does not score or rank programs.